Medtronic has received Health Canada approval for its Affera Integrated Mapping System and Sphere-9 Catheter for treating atrial fibrillation and atrial flutter. The licence allows commercial use of Medtronic's combined pulse field and radiofrequency ablation technologies across Canada. The Affera system provides physicians with an all-in-one mapping and ablation platform aimed at supporting procedural efficiency and patient care. The approval marks a milestone for Medtronic's Cardiac Ablation Solutions division in the global atrial fibrillation treatment market.
Medtronic PLCHealth Canada approval enables commercial use of Affera system in Canada.
